Skip to content

Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke

Ischemic Stroke | Patent Foramen Ovale | Bleeding Ulcer

To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 to 60

Participation Criteria

Inclusion Criteria:

* Successful transcatheter PFO closure with any approved device
* Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure

Exclusion Criteria:

-\>60 year-old

* RoPE score \<6
* Residual shunt ≥moderate following PFO closure
* Atrial fibrillation following PFO closure
* Presence of ≥2 cardiovascular risk factors (smoking, hypertension, dyslipidemia)
* Diabetes mellitus
* Thrombophilia (factor V Leiden, factor II mutation, anticardiolipin antibodies, lupus anticoagulant, anti-b2 glycoprotein-I antibodies, protein C deficiency, protein S deficiency)
* Recurrent cerebrovascular event (stroke, TIA) within the year following PFO closure
* Failure to provide signed informed consent
* Absolute contraindications for an MRI study

Study Location

IUCPQ
IUCPQ
Québec, Quebec
Canada

Contact Study Team

Primary Contact

Josep Rodes-Cabau, MD

[email protected]
4186568711
Backup Contact

Melanie Cote, MSc

[email protected]
4186568711
Study Sponsored By
Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
Participants Required
More Information
Study ID: NCT04475510